<DOC>
	<DOCNO>NCT02475278</DOCNO>
	<brief_summary>The purpose study collect serum sample evaluate serologic assay establish proficiency panel serologic assay use assessment post vaccination immune response intramuscular ( IM ) vaccination Norovirus GI.1/GII.4 bivalent virus-like particle ( VLP ) vaccine .</brief_summary>
	<brief_title>Serologic Assay Validation , Proficiency Testing , Safety Immunogenicity Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine</brief_title>
	<detailed_description>The vaccine test study call Norovirus GI.1/GII.4 bivalent Virus-Like Particle Vaccine ( NoV Vaccine ) . The purpose study collect serum sample evaluate serologic assay establish proficiency panel serologic assay use assessment post vaccination immune response intramuscular ( IM ) vaccination NoV vaccine . The validation proficiency test immunogenicity assay require support NoV Vaccine development program . This study also look side effect people administer single dose NoV vaccine . The study enrol 50 patient . All participant receive one dose NoV vaccine via intramuscular injection . Participants ask record symptom may relate vaccine injection site diary card 7 day receive vaccination . This single-centre trial conduct United States . The overall time participate study 183 day . Participants make 4 visit clinic , contact telephone 183 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>1 . Age 18 49 year , inclusive . 2 . Is good health time entry trial determine medical history , physical examination ( include vital sign ) clinical judgment investigator . 3 . Signs date write , informed consent form require privacy authorization prior initiation trial procedure , nature trial explain accord local regulatory requirement . 4 . Can comply trial procedure available duration followup . 5 . Body weight ≥50kg ( 110lbs ) . 6 . Body mass index ( BMI ) &lt; 35 . 1 . Has history acute gastroenteritis ( AGE ) within 14 day enrollment . 2 . Has previously expose experimental Norovirus ( NoV ) Vaccine . 3 . Has receive inactivate vaccine within 14 day live vaccine 28 day prior enrollment trial planning receive vaccine within 28 day investigational vaccine administration . 4 . Has contraindication , warning and/or precaution vaccination NoV Vaccine specify within investigator brochure . 5 . Has know hypersensitivity allergy NoV Vaccine component ( include excipients ) . 6 . Has behavioral cognitive impairment psychiatric disease , opinion investigator , may interfere participant 's ability participate trial . 7 . Has history progressive severe neurologic disorder , seizure disorder neuroinflammatory disease ( e.g . GuillainBarré syndrome ) . 8 . Has history illness , opinion investigator , might interfere result trial pose additional risk participant due participation trial . 9 . Has know suspect impairment/alteration immune function , include : 1 . Chronic use oral steroid ( Equivalent 20 mg/day prednisone ≥ 12 week / ≥ 2 mg/kg body weight / day prednisone ≥ 2 week ) within 60 day prior Day 1 ( use inhale , intranasal , topical corticosteroid allow ) . 2 . Receipt parenteral steroid ( Equivalent 20 mg/day prednisone ≥ 12 week / ≥ 2 mg/kg body weight / day prednisone ≥ 2 week ) within 60 day prior Day 1 . 3 . Administration immunoglobulins and/or blood product within three month precede first administration investigational vaccine plan administration trial ( consider whether applicable exclusion criterion criterion delay ) . 4 . Receipt immunostimulants within 60 day prior Day 1 . 5 . Receipt parenteral , epidural intraarticular immunoglobulin preparation , blood product , and/or plasma derivates within 3 month prior Day 1 plan full length trial . 6 . Human immunodeficiency virus ( HIV ) infection HIVrelated disease . 7 . Genetic immunodeficiency . 10 . Has abnormalities splenic thymic function . 11 . Has know bleed diathesis , condition may associate prolonged bleeding time . 12 . Has serious chronic progressive disease accord judgment investigator ( e.g . neoplasm , insulin dependent diabetes , cardiac , renal hepatic disease ) . 13 . Is participate clinical trial another investigational product 30 day prior first trial visit intent participate another clinical trial time conduct trial . 14 . Is involve trial conduct first degree relative . 15 . Has history substance alcohol abuse within past 2 year . 16 . Females pregnant breastfeeding . 17 . If female childbearing potential , sexually active , use `` acceptable contraceptive method '' least 2 month prior trial entry : 1 . Of childbearing potential defined status post onset menarche meeting follow condition : menopausal least 2 year , status bilateral tubal ligation least 1 year , status bilateral oophorectomy , status hysterectomy . 2 . Acceptable birth control method define one following : i. Hormonal contraceptive ( oral , injection , transdermal patch , implant , cervical ring ) . ii . Barrier ( condom spermicide diaphragm spermicide ) every time intercourse . iii . Intrauterine device ( IUD ) . iv . Monogamous relationship vasectomize partner . Partner must vasectomize least six month prior participant ' trial entry . 18 . If female childbearing potential sexually active , refusal use `` acceptable contraceptive method '' 6 month receipt investigational vaccine . In addition , must advise donate ova period . 19 . Any positive indeterminate pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>